Showing results (41-50 of 50) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 27, 2020
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse eventsCarsten Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 19, 2012
Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trialBaroukh M Assael, Tacjana Pressler, Diana Bilton, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 9, 2016
Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trialJochen G Mainz, Ulrike Schumacher, Katja Schädlich, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 8, 2016
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patientsPatrick A Flume, Donald R VanDevanter, Elizabeth E Morgan, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2015
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsJ Stuart Elborn, David E Geller, Douglas Conrad, et al.ERJ Open Research|October 30, 2020
Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b studySilke van Koningsbruggen-Rietschel, Jane C Davies, Tacjana Pressler, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 10, 2019
GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN)Silke van Koningsbruggen-Rietschel, Katja Conrath, Rainald Fischer, et al.Clinical and Translational Allergy|June 19, 2015
Influence of alpine mountain climate of Bavaria on patients with atopic diseases: studies at the Environmental Research Station Schneefernerhaus (UFS - Zugspitze) - a pilot studyBernadette Eberlein, Johannes Huss-Marp, Florian Pfab, et al.Plos One|February 24, 2015
Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database studyMarietta Rottenkolber, Eef Voogd, Liset van Dijk, et al.The Lancet. Respiratory Medicine|February 13, 2021
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension studyPatrick A Flume, Reta Fischer Biner, Damian G Downey, et al.Pageof 5